Author name: Enigmatic Code

We are thrilled to share that Prof. Nicolas Van Mieghem from Erasmus MC (Rotterdam, the Netherlands) has presented the latest advancements of the Approxima technology at Miami Valves 2025 on Feb 1st

Milan, Italy, June 3, 2025 – Approxima Srl announced today the appointment of Rick Geoffrion, seasoned MedTech entrepreneur as an independent Board Director. Rick Geoffrion has more than 35 years of management experience in the medical device industry  and more specifically in the cardiovascular device space. Mr. Geoffrion has previously led the company foundation for

Milan, Italy, February 20, 2025 – Approxima Srl announced today the first closing of a Series A financing round securing € 7.3M. The round was co-lead by ENEA Tech e Biomedical and Panakès Partners with strong continued support from current shareholders Club degli Investitori and other business angels. The round remains open for subscription from

We are thrilled to announce that Approxima has been selected as one of the top innovators in the medtech industry, earning us a spot to showcase our technology at the prestigious MedTech Innovator Road Tour 2024 in Dublin on April 15, during the International Pitch Event.

Approxima is currently participating in the MedTech Strategist Innovation Summit in Dublin 2024, a remarkable event for medtech innovations.

We are delighted to inform you that Dr. Paolo Denti, our Chief Medical Officer, will be presenting the latest advancements of the Approxima technology at the upcoming hasztag#InnovatorsDay and hasztag#EuroPCR conference in Paris next week! 🔍 Our ePoster will be displayed throughout the duration of both Innovators Day and Euro PCR on touchscreens, offering attendees

We are honoured to announced that the Scientific Board of Approxima has been joined by two interventional cardiologists distinguished KOLs in the structural heart field:– Prof. Nicolas Van Mieghem – Full Professor of Inteventional Cardiology at Erasmus MC in Rotterdam, Netherlands– Dr. Federico De Marco – Director of Interventional, Valvular and Structural Heart Cardiology at

Approxima closed a € 1.6M seed financing round for the development of its minimally invasive tricuspid valve repair technology and strengthens the team with both a new Chairman of the Board and a CMO. • The seed financing round was led by Panakès Partners alongside Club degli Investitori and a group of business angels. •